Västra Hamnen Corp. Finance

Lipum: Progress towards the next phase

• Final patient dosed in the phase I study
• Production process of SOL-116 according to plan
• Adjusting the WACC leads to a new fair value of SEK 15.19 (10.81) per share

During the third quarter, Lipum reported continued progress in its clinical programme with the drug candidate SOL-116 in rheumatoid arthritis (RA). Most significantly, the last patient in the ongoing phase I study was included and dosed. This means all participants and patients have been included and the study advances towards completion.

In summary, the model changes have led to a higher fair value, SEK 15.19 (10.81) per share. The full report is available here.

Datum 2024-10-29, kl 15:00
Källa MFN
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet